Evidence map›Paper›PMID 38922557›Full record

ArticleAngiogenesis2024

Botulinum neurotoxin serotype A inhibited ocular angiogenesis through modulating glial activation via SOCS3.

Austin T Gregg, Tianxi Wang, Manon Szczepan, Enton Lam, Hitomi Yagi, Katherine Neilsen, Xingyan Wang, Lois E H Smith, Ye Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Angiogenesis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Austin T Gregg *Department of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Tianxi Wang *Department of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Manon SzczepanDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Enton LamDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Hitomi YagiDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Katherine NeilsenDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Xingyan WangDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Lois E H SmithDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA. lois.smith@childrens.harvard.edu.
Ye SunDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA. ye.sun@childrens.harvard.edu.

Funding

Dietary control of angiogenesis in retinopathy modelsR01EY017017 · NEI · BOSTON CHILDREN'S HOSPITAL · PI Zhongjie Fu, Lois Smith · 2006 to 2026
$11.8M
Genetic Analysis and Manipulation Core (GAEC)P50HD105351 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI Hisashi Umemori · 2021 to 2026
$9.4M
Mouse Neurodevelopmental Behavior CoreU54HD090255 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI POMEROY, SCOTT LOREN · 2016 to 2020
$5.2M
Photoreceptor Determination of Retinal Blood Vessel Growth in RetinopathyR01EY029238 · NEI · BOSTON CHILDREN'S HOSPITAL · PI YE SUN · 2019 to 2026
$2.6M
The Mechanism of Immune-Vascular Crosstalk in RetinopathyR01EY030140 · NEI · BOSTON CHILDREN'S HOSPITAL · PI SUN, YE · 2019 to 2023
$2.0M
Glucose/lipid metabolism and vessel development in phase I ROPR01EY030904 · NEI · BOSTON CHILDREN'S HOSPITAL · PI SMITH, LOIS · 2020 to 2023
$1.7M
NEI NIH HHS R01 EY017017NEI NIH HHS R01 EY029238NEI NIH HHS R01 EY030140NEI NIH HHS R01 EY030904NICHD NIH HHS P50 HD105351NICHD NIH HHS U54 HD090255
6 · The paper itself

Abstract

backgroundPathological angiogenesis causes significant vision loss in neovascular age-related macular degeneration and other retinopathies with neovascularization (NV). Neuronal/glial-vascular interactions influence the release of angiogenic and neurotrophic factors. We hypothesized that botulinum neurotoxin serotype A (BoNT/A) modulates pathological endothelial cell proliferation through glial cell activation and growth factor release.

methodsA laser-induced choroidal NV (CNV) was employed to investigate the anti-angiogenic effects of BoNT/A. Fundus fluorescence angiography, immunohistochemistry, and real-time PCR were used to assess BoNT/A efficacy in inhibiting CNV and the molecular mechanisms underlying this inhibition. Neuronal and glial suppressor of cytokine signaling 3 (SOCS3) deficient mice were used to investigate the molecular mechanisms of BoNT/A in inhibiting CNV via SOCS3.

findingsIn laser-induced CNV mice with intravitreal BoNT/A treatment, CNV lesions decreased > 30%; vascular leakage and retinal glial activation were suppressed; and Socs3 mRNA expression was induced while vascular endothelial growth factor A (Vegfa) mRNA expression was suppressed. The protective effects of BoNT/A on CNV development were diminished in mice lacking neuronal/glial SOCS3.

conclusionBoNT/A suppressed laser-induced CNV and glial cell activation, in part through SOCS3 induction in neuronal/glial cells. BoNT/A treatment led to a decrease of pro-angiogenic factors, including VEGFA, highlighting the potential of BoNT/A as a therapeutic intervention for pathological angiogenesis in retinopathies.

Indexed as

Botulinum Toxins, Type AChoroidal NeovascularizationNeurogliaSuppressor of Cytokine Signaling 3 ProteinAngiogenesisAnimalsMiceMice, Inbred C57BLMice, KnockoutSuppressor of Cytokine Signaling ProteinsVascular Endothelial Growth Factor ABotulinum Toxins, Type ASocs3 protein, mouseSuppressor of Cytokine Signaling 3 ProteinSuppressor of Cytokine Signaling ProteinsVascular Endothelial Growth Factor AAge-related macular degenerationBotulinum neurotoxin serotype AChoroidal neovascularizationGlial activationMicroglial activationMüller activationSOCS3

Identifiers

PMID38922557
PMCPMC11564384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.